Literature DB >> 9142729

Comparison of three different methods for radiolabelling human activated T lymphocytes.

C Botti1, D R Negri, E Seregni, V Ramakrishna, F Arienti, L Maffioli, C Lombardo, A Bogni, C Pascali, F Crippa, S Massaron, F Remonti, S Nerini-Molteni, S Canevari, E Bombardieri.   

Abstract

One approach in the treatment of ovarian cancer patients involves the infusion of autologous T lymphocytes coupled with a bispecific monoclonal antibody MOv18/anti-CD3 (biMAb OC/TR), which recognizes a 38-kDa glycoprotein expressed on ovarian carcinomas and the CD3 T cell receptor. However, little is known about the in vivo biodistribution of injected activated lymphocytes, information that could be obtained by scintigraphic imaging of radiolabelled T cells in order to visualize the migratory pattern. We compared the efficiency, stability and toxicity of technetium-99m hexamethylpropylene amine oxime (HMPAO), indium-111 oxine and fluorine-18 2-fluoro-2-deoxy-d-glucose (FDG) in radiolabelling activated lymphocytes targeted with biMAb OC/TR. The mean labelling efficiencies of 111In-oxine and 18F-FDG using 2.5x10(8) lymphocytes (68% and 64%, respectively) were more than twice that of 99mTc-HMPAO (31%). Retention of the radionuclide in the cell was highest in the case of 111In-oxine labelling (less than 25% of the initial cell-bound activity released after 240 min, as compared with 44% of the 99mTc label in the same period and 45% of 18F radionuclide released after 150 min). None of the three radiolabelling reagents induced any significant alteration in cell viability or immunophenotype. However, both 111In-oxine and 18F-FDG induced a loss of cytotoxic activity of lymphocytes against the ovarian carcinoma cell line IGROV1, and all three radiolabelling reagents caused a significant reduction in the proliferative ability of labelled lymphocytes compared to controls, with cell death occurring after 8-9 days. Radiolabelling with the more stable 111In-oxine reagent using a higher number of lymphocytes (1.4x10(9)) but the same total activity (around 55.5 MBq) resulted in improved labelled T cell viability and proliferative ability, although the mean labelling efficiency decreased (35.8%). Together the data suggest that 111In-oxine at low activity per cell is the most appropriate reagent for radiolabelling activated retargeted T lymphocytes useful for in vivo biodistribution studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142729     DOI: 10.1007/bf01267680

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  33 in total

1.  Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma.

Authors:  Birgit Meller; Christoph Frohn; Jörg-Matthias Brand; Isabel Lauer; Lutz F Schelper; Katharina von Hof; Holger Kirchner; Eckart Richter; Manfred Baehre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-19       Impact factor: 9.236

2.  Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells.

Authors:  Sabrina Chiesa; Silvia Morbelli; Sara Morando; Michela Massollo; Cecilia Marini; Arinna Bertoni; Francesco Frassoni; Soraya Tabera Bartolomé; Gianmario Sambuceti; Elisabetta Traggiai; Antonio Uccelli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-29       Impact factor: 11.205

3.  The role of molecular imaging in the development of dendritic cell-based cancer vaccines.

Authors:  Giovanni Lucignani; Maria Rescigno
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

Review 4.  Noninvasive PET Imaging of T cells.

Authors:  Weijun Wei; Dawei Jiang; Emily B Ehlerding; Quanyong Luo; Weibo Cai
Journal:  Trends Cancer       Date:  2018-04-17

Review 5.  The Immunoimaging Toolbox.

Authors:  Aaron T Mayer; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2018-05-24       Impact factor: 10.057

6.  In-vivo comparison of the acute retention of stem cell derivatives and fibroblasts after intramyocardial transplantation in the mouse model.

Authors:  Cajetan Lang; Sebastian Lehner; Andrei Todica; Guido Boening; Mathias Zacherl; Wolfgang-Michael Franz; Bernd Joachim Krause; Peter Bartenstein; Marcus Hacker; Robert David
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-26       Impact factor: 9.236

Review 7.  Imaging of cells and nanoparticles: implications for drug delivery to the brain.

Authors:  Katica Stojanov; Inge S Zuhorn; Rudi A J O Dierckx; Erik F J de Vries
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

8.  64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET.

Authors:  Christoph M Griessinger; Andreas Maurer; Christian Kesenheimer; Rainer Kehlbach; Gerald Reischl; Walter Ehrlichmann; Daniel Bukala; Maren Harant; Funda Cay; Jürgen Brück; Renate Nordin; Ursula Kohlhofer; Hans-Georg Rammensee; Leticia Quintanilla-Martinez; Martin Schaller; Martin Röcken; Bernd J Pichler; Manfred Kneilling
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-13       Impact factor: 11.205

9.  PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine.

Authors:  Michael R Weist; Renate Starr; Brenda Aguilar; Junie Chea; Joshua K Miles; Erasmus Poku; Ethan Gerdts; Xin Yang; Saul J Priceman; Stephen J Forman; David Colcher; Christine E Brown; John E Shively
Journal:  J Nucl Med       Date:  2018-05-04       Impact factor: 10.057

10.  Cell tracking and therapy evaluation of bone marrow monocytes and stromal cells using SPECT and CMR in a canine model of myocardial infarction.

Authors:  Gerald Wisenberg; Katie Lekx; Pam Zabel; Huafu Kong; Rupinder Mann; Peter R Zeman; Sudip Datta; Caroline N Culshaw; Peter Merrifield; Yves Bureau; Glenn Wells; Jane Sykes; Frank S Prato
Journal:  J Cardiovasc Magn Reson       Date:  2009-04-27       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.